Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Hunterase

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. The patient has a diagnosis of Hunter syndrome based upon biochemical criteria:~   * as measured in plasma, leukocytes, or fibroblasts,~     * a deficiency in iduronate-2-sulfatase (I2S) enzyme activity of ≤ 10 % of the lower limit of the normal range~  * That corresponds to one or more of the following:~     * a normal enzyme activity level of one other sulfatase~    * Confirmed as MPS2 by genetic test results~    * shows clinical symptoms/ visible signs of MPS2~2. \< 6 years old and male~3. Patients who are able to comply with the study requirements~4. The patient's parent(s), or patient's legal guardian must have given voluntary written consent to participate in the study~Exclusion Criteria:~1. The patient has had a tracheostomy~2. The patient has known severe hypersensitivity or shock to any of the components of idursulfase~3. The patient has received treatment with another investigational therapy within 30 days prior to enrollment~4. History of a stem cell transplant~5. The patient has known severe hypersensitivity or shock to any of the components of test drug(excipient etc)

- Gender: MALE
- Minimum Age: None
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Test drug (Type: EXPERIMENTAL): Idursulfase-beta

Based on this trial design, predict the completion outcome and termination type (if applicable).